newsfilter
← Earnings
Earnings Releases·

Ultragenyx Pharmaceutical Inc. — Third Quarter 2026 Earnings Summary

Ultragenyx Pharmaceutical reported third-quarter 2026 total revenue of $173 million, driven by $109 million in CRYSVITA sales and $30 million in DOJOLVI sales. The company secured FDA approvals for its gene therapies GENGLYCOS and FAYUVI, selling the associated Priority Review Vouchers for a combined $413 million. To support a transition toward profitability in 2027, Ultragenyx initiated substantial expense reductions, including a 20% workforce cut and the termination of the UX701 program.

Company
ULTRAGENYX PHARMACEUTICAL INC
Sector
Healthcare
Industry
Biotechnology